TECHNOLOGY PLATFORMS：

We have established proprietary technology platforms that encompass the discovery, process development and production of biologics, enabling support from early research through commercialization. The effectiveness of this comprehensive and scalable approach is showcased by our diverse product pipeline and by several high-tech,commercially promising drug candidates in the fields of assisted reproductive drugs and ophthalmic drugs.

Drug Discovery Technology Platform：

In our drug discovery, we have established an advanced Tetrahedral DNA Nanostructures (TDN) platform, a core technological platform for innovative molecular R&D. This platform leverages the unique properties of DNA tetrahedra,which are self-assembled from four single-stranded DNA molecules. These structures are designed to possess specific sequences, dimensions, spatial conformations, and biological characteristics. Such designs enabled our TDN platform to directly modulate disease-associated genes at the RNA or DNA level, offering a more comprehensive and potentially curative approach than conventional small molecule and large molecule drugs primarily targeted at disease-related proteins.

Advanced Precision Control Process Development Platform：

Our advanced precision control process development platform leverages the unique characteristics of biologics research and our technological expertise to allow rapid adjustment of process parameters in response to changing production conditions. This platform fully supports the development of high-tech protein drugs in the fields of assisted reproduction and ophthalmology. Specifically, it includes:Complex glycoprotein process development technology,Enzyme protein process development technology,Long-acting drug development technology.

One-stop Production Technology Platform：

In our production process, we have independently established a one-stop production technology platform, leveraging our self-built advanced production facilities and efficient processes. This platform includes both eukaryotic and prokaryotic expression systems, allowing for large-scale production with significant capacity for industrial-scale manufacturing and ensuring a stable and cost-effective product supply. These production lines are designed to meet the specific characteristics of biopharmaceutical manufacturing in our key focus areas, while incorporating ongoing cost control strategies and robust supply chain management.